Search This Blog

Thursday, December 29, 2022

Mayflower, Cellectis to Develop Gene Editing Platform for Mitochondrial Diseases

 Following the formation of Mayflower Bioventures, a cell and gene therapy accelerator stood up from Hibiscus BioVentures and Mayo Clinic, comes the launch of their first start-up, Primera Therapeutics, Inc. (Primera). Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and gene therapies, and Primera announced today the execution of a Collaboration Agreement under which the Parties will work collaboratively to edit mutations in the mitochondrial DNA (mtDNA) in vivo to treat the root cause of associated diseases.

https://finance.yahoo.com/news/mayflower-bioventures-launches-first-spin-213000375.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.